Opposing effects of delta- and zeta-protein kinase C isozymes on cardiac fibroblast proliferation: use of isozyme-selective inhibitors - PubMed (original) (raw)
Comparative Study
Opposing effects of delta- and zeta-protein kinase C isozymes on cardiac fibroblast proliferation: use of isozyme-selective inhibitors
Martin Ulrich Braun et al. J Mol Cell Cardiol. 2003 Aug.
Abstract
Neonatal primary cardiac fibroblasts in defined medium continue to proliferate. Here, we show that phorbol ester inhibited and transforming growth factor-beta1 (TGFbeta1) stimulated this fibroblast proliferation. Cardiac fibroblasts contain six protein kinase C (PKC) isozymes: alpha-, delta-, epsilon-, betaI-, betaII-, and zeta-PKC. To evaluate the effect of different PKC isozymes on the proliferation of these cells, we used isozyme-selective PKC inhibitors. Inhibition of endogenous delta-PKC with deltaV1-1, an isozyme-selective translocation inhibitor, resulted in increased basal thymidine incorporation by 58 +/- 12% of control cells, but did not affect TGFbeta1-induced cell growth. Inhibition of endogenous zeta-PKC in neonatal rat cardiac fibroblasts with zeta-pseudosubstrate, a selective inhibitor for the atypical PKC isozymes, revealed an opposite effect; this inhibitor reduced basal growth to 45 +/- 11% and TGFbeta1-induced growth to 61 +/- 10%. Other isozyme-specific inhibitors used in this study did not alter basal or TGFbeta1-stimulated fibroblast growth. Taken together, our data provide evidence that delta-PKC inhibits and zeta-PKC stimulates proliferation of neonatal rat cardiac fibroblasts.
Similar articles
- EGF-induced ERK phosphorylation independent of PKC isozymes in human corneal epithelial cells.
Xu KP, Dartt DA, Yu FS. Xu KP, et al. Invest Ophthalmol Vis Sci. 2002 Dec;43(12):3673-9. Invest Ophthalmol Vis Sci. 2002. PMID: 12454035 - Chronic hypoxia induces exaggerated growth responses in pulmonary artery adventitial fibroblasts: potential contribution of specific protein kinase c isozymes.
Das M, Dempsey EC, Bouchey D, Reyland ME, Stenmark KR. Das M, et al. Am J Respir Cell Mol Biol. 2000 Jan;22(1):15-25. doi: 10.1165/ajrcmb.22.1.3536. Am J Respir Cell Mol Biol. 2000. PMID: 10615061 - Protein kinase C isozymes as potential targets for anticancer therapy.
Hofmann J. Hofmann J. Curr Cancer Drug Targets. 2004 Mar;4(2):125-46. doi: 10.2174/1568009043481579. Curr Cancer Drug Targets. 2004. PMID: 15032665 Review. - Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside.
Bosco R, Melloni E, Celeghini C, Rimondi E, Vaccarezza M, Zauli G. Bosco R, et al. Mini Rev Med Chem. 2011 Mar;11(3):185-99. doi: 10.2174/138955711795049899. Mini Rev Med Chem. 2011. PMID: 21534929 Review.
Cited by
- Trypanosoma cruzi Dysregulates piRNAs Computationally Predicted to Target IL-6 Signaling Molecules During Early Infection of Primary Human Cardiac Fibroblasts.
Cooley A, Rayford KJ, Arun A, Villalta F, Lima MF, Pratap S, Nde PN. Cooley A, et al. Immune Netw. 2022 Dec 2;22(6):e51. doi: 10.4110/in.2022.22.e51. eCollection 2022 Dec. Immune Netw. 2022. PMID: 36627941 Free PMC article. - Role and Mechanism of PKC-δ for Cardiovascular Disease: Current Status and Perspective.
Miao LN, Pan D, Shi J, Du JP, Chen PF, Gao J, Yu Y, Shi DZ, Guo M. Miao LN, et al. Front Cardiovasc Med. 2022 Feb 15;9:816369. doi: 10.3389/fcvm.2022.816369. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35242825 Free PMC article. Review. - Protein Kinase C-α Is a Gatekeeper of Cryptosporidium Sporozoite Adherence and Invasion.
McCowin S, Petri WA Jr, Marie C. McCowin S, et al. Infect Immun. 2022 Mar 17;90(3):e0067921. doi: 10.1128/iai.00679-21. Epub 2022 Jan 18. Infect Immun. 2022. PMID: 35099276 Free PMC article. - Evolving mechanisms of vascular smooth muscle contraction highlight key targets in vascular disease.
Liu Z, Khalil RA. Liu Z, et al. Biochem Pharmacol. 2018 Jul;153:91-122. doi: 10.1016/j.bcp.2018.02.012. Epub 2018 Feb 13. Biochem Pharmacol. 2018. PMID: 29452094 Free PMC article. Review. - Induction of GD3/α1-adrenergic receptor/transglutaminase 2-mediated erythroid differentiation in chronic myelogenous leukemic K562 cells.
Ha SH, Kang SK, Choi H, Kwak CH, Abekura F, Park JY, Kwon KM, Chang HW, Lee YC, Ha KT, Hou BK, Chung TW, Kim CH. Ha SH, et al. Oncotarget. 2017 Aug 9;8(42):72205-72219. doi: 10.18632/oncotarget.20080. eCollection 2017 Sep 22. Oncotarget. 2017. PMID: 29069780 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources